Clinical trials: Influenza in Humans
COVID-19
A Study to Evaluate the Safety and Immunogenicity of COVID-19 Vaccine and Influenza Combination Vaccine
This is a medical study where participants will be randomly assigned to receive either a new combination vaccine that protects against both COVID-19 and the flu, or a standard flu vaccine.
- Trial name
- NCT06291857
- Testing
- CIC Vaccine Co-formulated tNIV2 , SARSCoV-2 rS and Matrix-M Adjuvant, Novavax COVID-19 Vaccine, tNIV Vaccine
- Where
- 58 sites in Australia, New Zealand
- Volunteers
- 9,320 people, healthy volunteers welcome
- Sponsor
- Novavax
Influenza, Human
Safety and Immunogenicity Study of QIVc in Healthy Pediatric Subjects
This phase 3 clinical study is a randomized, observer-blind, comparator-controlled, multicenter study of QIVc versus a US-licensed comparator QIV in children 6 months through 47 months of age.
- Conditions
- Influenza, Human, Virus Diseases
- Trial name
- NCT04074928
- Testing
- QIVc, Comparator QIV
- Where
- 47 sites in United States
- Volunteers
- 2,414 people, healthy volunteers welcome
- Sponsor
- Seqirus
Orthomyxoviridae Infections, Influenza
Immunogenicity Study of the Influenza Vaccine in Adults
All marketed influenza vaccines are injected by the intramuscular (IM) route. This study will test whether an influenza vaccine is effective when injected by a route other than into the muscle.
- Trial name
- NCT00258934
- Testing
- Inactivated, split-virion influenza vaccine, Inactivated, split-virion, influenza virus
- Where
- 4 sites in Belgium, Germany and 1 more
- Volunteers
- 978 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Pandemic Influenza, Influenza A Virus Infection
Safety and Immunogenicity of H5N1 Adjuvanted, Inactivated, Split-Virion Pandemic Influenza Vaccine in Healthy Adults
The purpose of this study is to test different adjuvanted vaccine formulations as a two-dose schedule in immunologically naïve adults against one vaccine formulation without adjuvant in terms of tolerance and immunogenicity…
- Conditions
- Pandemic Influenza, Influenza A Virus Infection, Orthomyxoviridae Infections
- Trial name
- NCT00457509
- Testing
- A/H5N1 inactivated, split-virion influenza vaccine+Adjuvant, A/H5N1 inactivated, split-virion influenza vaccine
- Where
- 3 sites in Belgium
- Volunteers
- 251 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Influenza
A Prospective Epidemiological Study Evaluating Occurrences of Influenza-like Illness
This prospective epidemiological cohort study is being conducted in order to generate epidemiological data in support of Osivax's clinical development of a broad-spectrum influenza vaccine based upon the internal influenza…
- Trial name
- NCT06779981
- Testing
- Nasopharyngeal swabs
- Where
- Belgium
- Volunteers
- 119 people, healthy volunteers welcome
- Sponsor
- Osivax
Influenza
A Safety and Immunogenicity Trial in Adults 65 Years of Age or Over to Prevent Influenza
The objective of this study is to evaluate the safety of the vaccine and the immune response to the vaccine in healthy adult volunteers 65 years of age or older.
- Trial name
- AVX502-003 (NCT00706732)
- Testing
- AVX502
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- AlphaVax, Inc.
Influenza Prevention
The Safety and Immunogenicity Evaluation of Live Attenuated Influenza Vaccine
Live Attenuated freeze-dried Influenza Vaccine has been licensed for use in 2020 (Approval No.S20200002), the sponsor of this research submitted an new application for non freeze-dried Live Attenuated Influenza Vaccine in 2021.
- Trial name
- NCT05284851
- Testing
- Live Attenuated Influenza Vaccine(non freeze-dried), Live Attenuated Influenza Vaccine(freeze-dried)
- Where
- China
- Volunteers
- 2,520 people, healthy volunteers welcome
- Sponsor
- Changchun BCHT Biotechnology Co.
Influenza
Safety, Immunogenicity, and Relative Efficacy of H1N1 Vaccines in Adults Aged 18 Years and Older
The purpose of this study is to characterize the safety, immunogenicity, and relative efficacy of the H1N1 (swine) flu vaccines GSK2340273A and GSK2340274A in adults 18 years of age or older.
- Trial name
- NCT00979602
- Testing
- GSK2340274A, GSK2340273A
- Where
- 38 sites in United States, Canada
- Volunteers
- 4,048 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
Immunogenicity and Safety of a Vaccine Against Influenza (2010-2011 Northern Hemisphere Season, Intramuscular Route)
The aim of this study is to evaluate the new formulation of the influenza vaccine for the 2010-2011 Northern Hemisphere (NH) season in terms of immunogenicity and safety in the corresponding population and to check its compliance…
- Trial name
- NCT01121822
- Testing
- Influenza virus vaccine (split virion, inactivated)
- Where
- 3 sites in France
- Volunteers
- 129 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Influenza, Human
Study of Single Dose GHB16L2 Trivalent Influenza Vaccine in Healthy Adults
The purpose of this phase I/II trial is to evaluate safety and tolerability of a single dose of GHB16L2 administered by liquid nasal spray for vaccination against seasonal influenza virus infection.
- Trial name
- NCT01369862
- Testing
- GHB16L2
- Where
- Austria
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- AVIR Green Hills Biotechnology AG
Influenza, Swine-origin A/H1N1 Influenza
A Study of Inactivated Swine-Origin A/H1N1 Influenza Vaccines in Healthy European Subjects Aged 3 to 17 Years
The purpose of this study is to generate data on immunogenicity and safety of the monovalent H1N1 vaccine in support of the development and registration.
- Trial name
- NCT00956202
- Testing
- Swine A/H1N1 influenza vaccine (split virion, inactivated), Swine A/H1N1 influenza vaccine (split virion, inactivated + Adjuvant)
- Where
- 15 sites in Finland
- Volunteers
- 303 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Influenza
A Re-licensing Study to Assess the Efficacy of Inflexal V Formulated With WHO Recommended 2010/2011 Influenza Virus Strains for the Northern Hemisphere
A study to assess whether the Northern Hemisphere 2010/2011 season influenza vaccine Inflexal V fulfills the EMEA requirements for re-registration of influenza vaccines
- Trial name
- NCT01306305
- Testing
- Inflexal V
- Where
- Switzerland
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- Crucell Holland BV
Influenza
A Study of VIS410 to Assess Safety and Pharmacokinetics
The purpose of this study is to assess the safety, tolerability, immunogenicity and pharmacokinetics of single escalating doses of VIS410 in healthy volunteers.
- Trial name
- NCT02045472
- Testing
- VIS410
- Where
- United States
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- Visterra, Inc.
Severe Sepsis
Symphony IL-6 Study in Patients at Risk of Severe Sepsis
Symphony IL-6 is a device that quantitates human IL-6 by fluorescence enzyme immunoassay (FEIA) from whole-blood specimens. Use of Symphony IL- 6 removes the need for plasma separation before testing.
- Trial name
- NCT05665153
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Bluejay Diagnostics, Inc.
Influenza
Phase 1b Influenza Vaccine Study in Healthy Subjects
The purpose of this study is to see whether a single vaccination (injection) with the investigational influenza vaccine is safe in healthy subjects.
- Trial name
- NCT01181336
- Testing
- Influenza vaccine (FLU-v), FLU-v Control
- Where
- United Kingdom
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- PepTcell Limited
Influenza, Orthomyxoviridae Infections
A Study of the Immunogenicity and Safety of the 2006-2007 Influenza Vaccine
This study is designed to generate clinical data as outlined in the Note for Guidance on harmonization requirements for influenza vaccine marketing authorization by the European Medicines Agency.
- Trial name
- NCT00343681
- Testing
- Inactivated influenza vaccine (split virion)
- Where
- 2 sites in Switzerland, United Kingdom
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Influenza Disease
Safety, Tolerability, and Immunogenicity of the Adjuvanted Trivalent Subunit Influenza Vaccine and the Non-Adjuvanted Trivalent Subunit Influenza Vaccine Compared to the Non-Adjuvanted Trivalent Split Influenza Vaccine in Children 6 to < 72 Months of Age
This Study Aims to Evaluate the Safety, Tolerability, and Immunogenicity of the Adjuvanted Trivalent Subunit Influenza Vaccine and the Non-Adjuvanted Trivalent Subunit Influenza Vaccine Compared to the Non-Adjuvanted Trivalent…
- Trial name
- NCT01346592
- Testing
- Trivalent split influenza vaccine (TIV), MF59-adjuvanted trivalent influenza vaccine (aTIV), Licensed comparator trivalent split influenza vaccine (comparator TIV)
- Where
- 34 sites in Argentina, Australia and 3 more
- Volunteers
- 6,104 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Influenza, Human
A Study to Evaluate the Effect of a Single Oral Dose of ZX-7101A on the QTc Interval in Healthy Subjects
The purpose of this study is to evaluate the effect of a single oral dose of ZX-7101A on the QTc interval in healthy subjects.
- Trial name
- QTc-ZX-7101A (NCT05955027)
- Testing
- ZX-7101A
- Where
- China
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Nanjing Zenshine Pharmaceuticals
Influenza
A Double-Dose Safety Study of An Influenza Vaccine (Multimeric-001) Injected to Elderly Volunteers
This is a phase I/II, randomized, single-blind, placebo-controlled escalating double-dose study of the safety and priming potential of an intramuscular Influenza vaccine (Multimeric-001) injected to elderly volunteers.
- Trial name
- NCT01010737
- Testing
- Multimeric-001 250 mcg, Adjuvanted Multimeric-001 250mcg, Adjuvant: Montonide isa 51 VG
- Where
- Israel
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- BiondVax Pharmaceuticals ltd.
Influenza, Acute Respiratory Viral Infections
Study to Assess Efficacy and Safety of XC221 200 mg in the Treatment of Influenza or Other ARVI
The innovative drug XC221 is planned for use in treatment of acute respiratory viral infections in a double-blind, randomized, placebo-controlled, comparative multicenter study assessing the safety, tolerability and efficacy of…
- Trial name
- NCT03830905
- Testing
- XC221
- Where
- 16 sites in Russia
- Volunteers
- 120 people
- Sponsor
- PHARMENTERPRISES LLC